The many worlds of reducing interleukin-1

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 1960-1967

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE ACTIVATION; DISEASE ACTIVITY; EDITORIAL; OSTEOARTHRITIS; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 22244475444     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21107     Document Type: Editorial

References (42)

1. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52.
2. Goupille P, Giraubeau B, Conrozier T, Marliere J, Kiefer P, Chevalier X. Safety and efficacy of intra-articular injection of IL-1ra (IL-1 receptor antagonist) in patients with painful osteoarthritis of the knee: a multicenter, double blind study [abstract]. Arthritis Rheum 2003;48 Suppl 9:S696.
3. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc Natl Acad Sci U S A 2004;101:9745-50.
4. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN. Tschopp J. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 2004;20:319-25.
5. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
6. Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel [letter]. Arthritis Rheum 2004;0: 3738-9.
7. Dailey NJ, Aksentijeich I, Chae JJ, Wesley R, Snyder C, Magalnick M, et al. Interleukin-1 receptor antagonist anakinra in the treatment of neonatal onset multisystem inflammatory disease [abstract]. Arthritis Rheum 2004;50 Suppl 9:S440.
8. Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still's disease with anakinra. J Clin Rheumatol 2003;9:330-2.
9. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid, responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
10. Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult onset Still's disease [abstract]. Ann Rheum Dis 2004;63 Suppl 1:263.
11. Aelion JA, Odhav SK. Prompt response to treatment with anakinra in adult onset Still's disease [abstract]. Ann Rheum Dis 2004;63 Suppl 1:265.
12. Irigoyen PI, Olson J, Horn C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004;50 Suppl 9:S437.
13. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003;100:13501-6.
14. Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, et al. Beneficial response to interleukin-1 receptor antagonist in TRAPS. Am J Med 2004;117:208-10.
15. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12.
16. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85.
17. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004;10: 202-22.
18. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
19. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000;97:9203-8.
20. Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 2005;52:2202-11.
21. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
22. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
23. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
24. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
25. Malinowsky D, Lundkvist J, Laye S, Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998;429:299-302.
26. Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998;161:6871-7.
27. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003;18:87-96.
28. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J Biol Chem 1995;270: 13757-65.
29. Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-I receptor accessory protein. J Immunol 2000;164:5277-86.
30. Jensen LE, Whitehead AS. Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell Signal 2003;15: 793-802.
31. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
32. Nakae S, Asano M, Horai R, Iwakura Y. Interleukin-1β, but not interleukin-1α, is required for T-cell-dependent antibody production. Immunology 2001;104:402-9.
33. Nakae S, Naruse-Nakajima C, Sudo K, Horai R, Asano M, Iwakura Y. IL-1α, but not IL-1β, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int Immunol 2001;13:1471-8.
34. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1β is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A 1997;94:508-13.
35. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-Ia is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004;101:2434-9.
36. Buryskova M, Pospisek M, Grothey A, Simmet T, Burysek L, Intracellular interleukin-1α functionally interacts with histone acetyltransferase complexes. J Biol Chem 2004;279:4017-26.
37. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin-1 in macrophages. Proc Natl Acad Sci U S A 1985;82:1204-8.
38. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P, et al. Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 1994;84:4242-8.
39. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12.
40. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
41. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39:257-65.
42. Preas HL II, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996;88:2465-72.